At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label Randomized Study of Thymoglobulin Versus Daclizumab Induction Therapies for the Reduction of Acute Rejection in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
In Brief
A Phase 3 clinical trial evaluating Thymoglobulin, Daclizumab, and 6 other interventions for Kidney Failure, Chronic. Completed, enrolled 56 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether the anti-T cell antibody, Thymoglobulin is a more effective induction medication than the anti-IL-2R inhibitor daclizumab, in kidney transplant recipients who have a positive crossmatch with their live donor.
Study Details
Timeline
Interventions
Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
2 gm/day. Standard of care
To achieve serum level of 8-10 ng/ml.
100 mg intra-operatively, and 25 mg every 6h post-operatively for six doses
Taper over three months to 5 mg daily
Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered